Moberg Pharma and Menarini extend distribution agreement

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Feb 14, 2014 at 2:45 AM

Moberg Pharma and Menarini extend distribution agreement for Kerasal Nail to South East Asia

Moberg Pharma AB (OMX: MOB) today announced that A. Menarini Asia-Pacific Holdings Pte. Ltd, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Kerasal Nail™ in eight Southeast Asian countries. The extended distribution agreement builds on an existing collaboration between the two company groups, which resulted in a successful launch of the product in Italy and a previous extension of the distribution agreement for China. In Asia -Pacific, Menarini is a leading regional biopharmaceutical company with over 3500 employees in 13 markets and a strong track record in launching and promoting Consumer Health brands. The global sales of the Menarini Group exceed 3 billion Euros. The extension includes eight Southeast Asian countries: Singapore, Taiwan, Indonesia, Philippines, Malaysia, Hong Kong, Thailand and Vietnam. The added countries represents a market of more than 550 million people in one of the fastest growing regions in the world and represent a significant long term growth opportunity for Moberg Pharma. According to IMS[1] (http://connect.ne.cision.com#_ftn1), 45% of the global growth in self -medication up to 2016 will come from China and Southeast Asia. “I am very pleased to announce this agreement which meets one of our targets for 2014 - to enter the rapidly expanding Southeast Asian market. We enter this exciting opportunity together with Menarini Asia-Pacific - an ideal partner in the region. The region has huge potential and the agreement will contribute to revenues and earnings already in 2014”, said Peter Wolpert, CEO of Moberg Pharma AB. “We look forward to introducing Kerasal Nail™ to consumers in Southeast Asia. The product has potential to contribute strongly to our expansion within the Consumer Health market, being a compelling non-prescription product offering rapid visual improvement and an effective solution for patients with nail fungus problems”, said John A. Graham, CEO at Menarini Asia-Pacific. About Kerasal Nail™ and nail disease Kerasal Nail™ is a topical treatment used to treat nail disease. Launched in late 2010, it quickly became the market leader in the Nordics and recently also the best-selling product in its category in the U.S. The international launch is under way via a proprietary sales organization in the U.S. and ten partners that hold rights for 50 markets, including the major EU markets, China, Turkey and Russia. Kerasal Nail™ is a prescription-free, over-the-counter product sold under the names Kerasal Nail™, Naloc™/Nalox™ and Emtrix®. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Kerasal Nail™ has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease. The condition afflicts approximately 10 percent of the population and is more common among the elderly. It is generally recognized that there is a need for new efficacious and safe topical treatments. About this information Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:30 (CET) on February 14, 2014. [1] (http://connect.ne.cision.com#_ftnref1) AESGP 2012: Rising tide of OTC in Europe, IMS Health For further information, please contact: Peter Wolpert, CEO, Moberg Pharma AB, telephone: +46 707 35 71 35, e-mail: peter.wolpert@mobergpharma.se Peter Östling, IR, Moberg Pharma AB, telephone: +46 76 314 09 78; Email: peter.ostling@mobergpharma.se About Moberg Pharma AB Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with its own sales organization in the US and sales through distributors in more than 40 countries. The company’s OTC portfolio includes the brands Kerasal®, Jointflex®, Kerasal Nail™Domeboro®, Vanquish®, Fergon®and Kaprolac®. Kerasal Nail™(Nalox™ in many markets) is the leading product for the treatment of nail disorders in the U.S and Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergpharma.se. About Menarini Asia-Pacific Menarini is the world’s largest Italian biopharmaceutical company with a heritage of over 127 years and nearly 17,000 employees in over 100 countries. In Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia -Pacific operates across the entire commercial value chain, from regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Primary Care, Allergy/Respiratory, Cardiovascular, Oncology/Specialty Care and Men’s Health. For more information about Menarini Asia-Pacific, please visit www.menariniapac.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Innovative Sonar System Seeks to Simplify Fishing Boats

Navigating the Clutter on Fishing Boats You ever try setting up a sonar system on a fishing boat? It's like untangling a mess of Christmas lights. The cables, the hubs, the separate units—it’s chaos. Here's where a crafty inventor from Zumbro Falls, Minnesota, steps into the ring with an idea that's as refreshing as an ice-cold beer on a summer’s day: a centralized...

McKay Brothers Enhances Fastest Routes for Market Data

Breaking Down McKay Brothers' Latest Maneuver Yeah, the financial market isn't just numbers and screens—it's about moving those numbers faster than a cheetah chasing prey. McKay Brothers knows this game inside and out, and they're laying down new wires, or rather, wireless, to make sure they've got the quickest routes in the room. Let me tell you, they're throwing money...

EDB Enhances Postgres with Horizontal Scaling Preview

EDB's Ambitious Move Into Seamless Data Growth Right out of Wilmington, Delaware, EnterpriseDB (EDB) is sowing the seeds for a seismic change in how enterprises juggle their data systems. With 86% of the top brass anticipating AI data systems becoming top-tier indispensable, the unveiling of EDB’s horizontal scaling for their Postgres AI Distributed is a tune you just...

Rockford Fosgate Elevates Marketing Maverick to Lead Role

Changing the Guard in High-Performance Audio Marketing Out of Arizona, we get a shake-up that feels like a no-brainer for anyone in the high-performance audio market. Rockford Fosgate decided to elevate Tammy Lowe to the Vice President of Marketing role, effective immediately. With nearly four decades under her belt at the sunny Tempe-based HQ, it's hard to argue with the...

Navigating Homeowner Deductibles: Balancing Costs

Understanding the Basics: Premiums and Deductibles Picture sorting through bills with a cup of lukewarm coffee, wondering if there’s a smarter way to handle homeowner insurance. Chuck Montgomery cuts through the fluff, talking turkey about balancing insurance dollars. One part of the game is deciding your deductible, the sum you fork over before insurance steps in...

AuraQuantic Leads with No-Code Power in 2026 Analysis

Power Shift in No-Code Territory So here we are, taking a closer look at AuraQuantic's climb to the top in the low-code platform jungle. The SPARK Matrix™ by QKS Group just handed them the crown, naming them the Leader for business developers tinkering with these easy-to-use platforms. And, boy, we got some juicy details to chew on. Why AuraQuantic Stands Out The name...

JOIA Rose Hall Revives Jamaican Luxury Experience

A New Chapter for Jamaican Luxury If there's one thing that gets the blood pumping, it's a massive overhaul of a decades-old resort, especially one sitting pretty on Montego Bay's golden shores. December 1, 2026, marks the return of JOIA Rose Hall to the hospitality scene—shiny, revamped, and all about delivering an oasis fueled by authentic Jamaican culture. Forget...

Historic Williamsburg Loft Gets a Modern Makeover

Breathing New Life into a Brooklyn Classic Alright, picture this: You're stepping into a century-old Brooklyn loft, expecting dust, aged wood, maybe a ghost or two. What you actually find is art wrapped in brass with a splash of modern flair. This ain't just any loft, folks—it's the latest trophy on the mantle for Gallery KBNY, a design-build firm known for its...

Landis+Gyr's Q2 Gains and Future Strategies

Landis+Gyr's Multi-Faceted Financial Leap In the unpredictable landscape of energy tech, Landis+Gyr has thrown down some noteworthy cards in their latest financial disclosures. We're talking a Q2 net revenue sitting pretty at $269.2 million, and it's no mistake they landed a record-smashing adjusted gross margin of 38.0%. All this while wrangling an order intake of $170.3...

Marc Ryan Joins ABCS Insights as Chief Product Officer

Shaping the Future of Advertising Effectiveness In the ever-evolving ad measurement arena, where understanding what works can make or break a company, ABCS Insights has tossed a game-changing hat into the ring. They've just announced Marc Ryan as their new Chief Product Officer. Now, I’ve seen seasoned execs shuffle seats countless times, but this one’s...